- Grünenthal PRO enters non-exclusive partnership with SHL Medical on Molly® autoinjector services.
- New assembly lines at Origgio, Italy facility to launch in 2026, expanding CDMO capacity.
Grünenthal PRO, the contract development and manufacturing organisation (CDMO) division of Grünenthal, has announced a non-exclusive partnership with SHL Medical. The agreement will see Grünenthal PRO provide final assembly, packaging, and labelling for the Molly® autoinjector.
As part of the collaboration, Grünenthal PRO will expand its capacity by installing additional pre-validated assembly lines for Molly® 1.0 and 2.25 mL platforms at its Origgio, Italy site. These are expected to be operational in 2026, adding to the company’s decade-long experience in SHL autoinjector assembly services.
The partnership will enable SHL customers to access Grünenthal PRO’s expertise and established capabilities in contract manufacturing for injectable therapies. “Speed-to-market is a decisive advantage in today’s biopharma landscape,” said Victor Barbosa, Executive Vice President of Global Operations at Grünenthal. “With our deep expertise in autoinjector final assembly and the new high-speed line launching in 2026, Grünenthal is uniquely positioned to deliver agile, large-scale solutions.”
Molly®, a single-dose autoinjector platform from SHL, is designed to reduce initial investment and accelerate development timelines for pharmaceutical and biotech companies. It has been widely adopted in combination product approvals and is adaptable to future requirements.
The new assembly line will be procured from SHL Advantec, a subgroup of SHL Medical providing automation and tooling solutions for healthcare and other industries.
